Cargando…

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Detalles Bibliográficos
Autores principales:	Li, Pengfei, Wang, Yining, Lavrijsen, Marla, Lamers, Mart M., de Vries, Annemarie C., Rottier, Robbert J., Bruno, Marco J., Peppelenbosch, Maikel P., Haagmans, Bart L., Pan, Qiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771185/ https://www.ncbi.nlm.nih.gov/pubmed/35058606 http://dx.doi.org/10.1038/s41422-022-00618-w

Ejemplares similares

Immunosuppressants exert differential effects on pan‐coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir
por: Wang, Yining, et al.
Publicado: (2023)

Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids
por: Li, Pengfei, et al.
Publicado: (2022)

Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses
por: Li, Jiajing, et al.
Publicado: (2023)

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
por: Vangeel, Laura, et al.
Publicado: (2022)

Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response
por: Wang, Yining, et al.
Publicado: (2023)

Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions
por: Wang, Yining, et al.
Publicado: (2022)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
por: Wai, Abraham Ka-chung, et al.
Publicado: (2023)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
por: Zheng, Qinyue, et al.
Publicado: (2023)

Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations
por: Li, Pengfei, et al.
Publicado: (2022)

Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients
por: Li, Pengfei, et al.
Publicado: (2021)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
por: Cegolon, Luca, et al.
Publicado: (2023)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
por: Qiu, Chaochao, et al.
Publicado: (2023)

Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
por: Jeong, Ju Hwan, et al.
Publicado: (2022)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
por: Rosenke, Kyle, et al.
Publicado: (2023)

547. Molnupiravir and Nirmatrelvir/Ritonavir Effectiveness in Reducing the Risk for COVID-19 Disease Progression and Death
por: Paraskevis, Dimitrios, et al.
Publicado: (2023)

Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks
por: Li, Pengfei, et al.
Publicado: (2023)

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques
por: Rosenke, Kyle, et al.
Publicado: (2022)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
por: Cox, Robert M., et al.
Publicado: (2023)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
por: Butt, Adeel A, et al.
Publicado: (2023)

SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
por: Mykytyn, Anna Z, et al.
Publicado: (2021)

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
por: Ma, Bosco Hon-Ming, et al.
Publicado: (2023)

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
por: Han, Jaijun, et al.
Publicado: (2023)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
por: Park, Jin Ju, et al.
Publicado: (2023)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
por: Karniadakis, Ioannis, et al.
Publicado: (2023)

Mpox virus infects and injures human kidney organoids, but responding to antiviral treatment
por: Li, Pengfei, et al.
Publicado: (2023)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
por: Zou, Rongrong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m0cr4r0alrnfro0qb0ten4e6p8